Potrasertib

Potrasertib
Clinical data
Other names	IMP7068
Identifiers
	IUPAC name 7-(2,6-dichlorophenyl)-12-[3-methyl-4-[(3S,5R)-3,4,5-trimethylpiperazin-1-yl]anilino]-2,5,7,11,13-pentazatricyclo[7.4.0.02,6]trideca-1(13),5,9,11-tetraen-8-one;
CAS Number	2226938-19-6;
PubChem CID	139503236;
UNII	621K13UG4B;
Chemical and physical data
Formula	C28H30Cl2N8O
Molar mass	565.50 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1CN(C[C@@H](N1C)C)C2=C(C=C(C=C2)NC3=NC=C4C(=N3)N5CCN=C5N(C4=O)C6=C(C=CC=C6Cl)Cl)C;
	InChI InChI=InChI=1S/C28H30Cl2N8O/c1-16-12-19(8-9-23(16)36-14-17(2)35(4)18(3)15-36)33-27-32-13-20-25(34-27)37-11-10-31-28(37)38(26(20)39)24-21(29)6-5-7-22(24)30/h5-9,12-13,17-18H,10-11,14-15H2,1-4H3,(H,32,33,34)/t17-,18+; Key:BNVDJVMTLDUCGH-HDICACEKSA-N;

Potrasertib is an investigational new drug that is being evaluated by IMPACT Therapeutics for the treatment of advanced solid tumors. It is oral inhibitor of WEE1 kinase, a key regulator of cell cycle checkpoints.^[1]^[2]

References

^ "IMP 7068". AdisInsight. Springer Nature Switzerland AG.
^ Wang Z, Li W, Li F, Xiao R (January 2024). "An update of predictive biomarkers related to WEE1 inhibition in cancer therapy". Journal of Cancer Research and Clinical Oncology. 150 (1): 13. doi:10.1007/s00432-023-05527-y. PMC 10794259. PMID 38231277.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] "IMP 7068". AdisInsight. Springer Nature Switzerland AG.

[pmid38231277-2] Wang Z, Li W, Li F, Xiao R (January 2024). "An update of predictive biomarkers related to WEE1 inhibition in cancer therapy". Journal of Cancer Research and Clinical Oncology. 150 (1): 13. doi:10.1007/s00432-023-05527-y. PMC 10794259. PMID 38231277.

[1]

[2]